The nation of Zimbabwe has turned down a substantial US health deal worth 367 million US dollars (£272m) spanning five years due to the United States' demand for sensitive data.
This move was revealed after a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesman later clarified that the United States was demanding access to health data for research and commercial purposes but refused to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated over $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for further talks to reach a deal suitable to all parties so the country's vital HIV programme can be sustained.
Broader Background
Zimbabwe's decision follows a similar case in neighbouring Kenya, where a court blocked a similar health funding agreement after concerns were filed about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump argued its spending was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and responsibility.
According to reports, 16 African countries have so far agreed to similar agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, with no corresponding guarantee of access to any medical innovations – such as new medicines or tests – that could result from that shared data," he stated.
"Put simply, our nation would provide the basic resources for scientific discovery with no certainty that the final treatments would be accessible to our citizens should a new disease outbreak arise."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of bilateral deals were disrupting frameworks already established through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage future global health emergencies.
"This framework is intended to guarantee that when a country contributes its data, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to further discussions with our US partners on how future collaboration might be arranged in a manner that respects the independence and interests of both nations."
Health Experts Reaction
Medical experts expressed it acknowledged the official position, but suggested that talks need to persist given that a large portion of the nation's HIV programmes were funded by external financing.
"Where technical issues exist, such as those involving information security or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," it added.
The situation underscores the ongoing tensions between receiving crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.